Chronic kidney disease-mineral and bone disorder in children: From early mineral dysregulation to preservation of the growing skeleton

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic complication of CKD encompassing abnormalities of calcium, phosphate, parathyroid hormone (PTH), Vitamin D, and other regulators of mineral metabolism; disturbances in bone turnover, mineralization, and volume; impaired growth; fractures; and extraskeletal calcification. In children, CKD-MBD has particular importance because mineral dysregulation occurs during periods of active skeletal growth and peak bone-mass acquisition. The traditional model in which hyperphosphatemia, hypocalcemia, and secondary hyperparathyroidism occur only in advanced CKD has been replaced by recognition of much earlier alterations involving fibroblast growth factor 23, sclerostin, Klotho, and Vitamin D metabolism. Recent pediatric evidence demonstrates measurable CKD-MBD abnormalities from CKD stage 2, well before overt hyperphosphatemia or hypocalcemia. Clinical assessment should integrate growth, skeletal symptoms, and serial trends in calcium, phosphate, alkaline phosphatase, PTH, and 25-hydroxyvitamin D rather than relying on isolated values. Bone biopsy remains the reference standard for defining renal osteodystrophy, although its invasive nature limits routine use. The latest systematic review of pediatric renal osteodystrophy confirms that most biopsied children with CKD have histological abnormalities, with high-turnover disease predominating overall, but with substantial heterogeneity. Management requires a careful balance between providing sufficient calcium and phosphorus for the growing skeleton and avoiding calcium loading, hyperphosphatemia, secondary hyperparathyroidism, and vascular calcification. Nutritional Vitamin D deficiency should be corrected, active Vitamin D analogs individualized according to PTH trends, and calcimimetics reserved for selected children with persistent secondary hyperparathyroidism. Contemporary management therefore increasingly emphasizes early surveillance, individualized mineral balance, and prevention of both skeletal and cardiovascular consequences.

Authors

Institutions

Publication Details

Journal
World Advances in Renal Medicine
Published
2026-11-18
DOI
https://doi.org/10.25259/warm_26_2026
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Chronic kidney disease-mineral and bone disorder in children: From early mineral dysregulation to preservation of the growing skeleton

Naifain Al Kalbani, Sulaiman Al Saidi, Mohamed S. Al Riyami, Badria Al Ghaithi
World Advances in Renal Medicine
Parathyroid Disorders and Treatments
article

Chronic kidney disease-mineral and bone disorder in children: From early mineral dysregulation to preservation of the growing skeleton

Naifain Al Kalbani, Sulaiman Al Saidi, Mohamed S. Al Riyami, Badria Al Ghaithi
article en

Abstract

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic complication of CKD encompassing abnormalities of calcium, phosphate, parathyroid hormone (PTH), Vitamin D, and other regulators of mineral metabolism; disturbances in bone turnover, mineralization, and volume; impaired growth; fractures; and extraskeletal calcification. In children, CKD-MBD has particular importance because mineral dysregulation occurs during periods of active skeletal growth and peak bone-mass acquisition. The traditional model in which hyperphosphatemia, hypocalcemia, and secondary hyperparathyroidism occur only in advanced CKD has been replaced by recognition of much earlier alterations involving fibroblast growth factor 23, sclerostin, Klotho, and Vitamin D metabolism. Recent pediatric evidence demonstrates measurable CKD-MBD abnormalities from CKD stage 2, well before overt hyperphosphatemia or hypocalcemia. Clinical assessment should integrate growth, skeletal symptoms, and serial trends in calcium, phosphate, alkaline phosphatase, PTH, and 25-hydroxyvitamin D rather than relying on isolated values. Bone biopsy remains the reference standard for defining renal osteodystrophy, although its invasive nature limits routine use. The latest systematic review of pediatric renal osteodystrophy confirms that most biopsied children with CKD have histological abnormalities, with high-turnover disease predominating overall, but with substantial heterogeneity. Management requires a careful balance between providing sufficient calcium and phosphorus for the growing skeleton and avoiding calcium loading, hyperphosphatemia, secondary hyperparathyroidism, and vascular calcification. Nutritional Vitamin D deficiency should be corrected, active Vitamin D analogs individualized according to PTH trends, and calcimimetics reserved for selected children with persistent secondary hyperparathyroidism. Contemporary management therefore increasingly emphasizes early surveillance, individualized mineral balance, and prevention of both skeletal and cardiovascular consequences.

World Advances in Renal MedicineVol. 0
Royal Hospital (OM)
Good health and well-being
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon